These insights suggest that targeting Src signalling could provide neuroprotection in glaucoma, offering a strategy to counteract fibrosis-related damage, excitotoxicity, and oxidative stress, with Dock3 signalling as a promising therapeutic target. The gene discussed is DOCK3; the disease is glaucoma.